HEPA Hepion Pharmaceuticals, Inc.
Pharmaceutical Preparations · OTC · SEC CIK 1583771 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY20.4%
TTM EPS YoY98.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-166.9%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets180.2%
Debt / equity—
Current ratio4.43x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.28x
Accruals ratio-120.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $134,654 | $50,918 | $70,000 | $0 | $0 | $423,277 | $22,235 | -$591,608 |
| SG&A expense | $1.42M | $1.16M | $728,509 | $609,683 | $527,902 | $919,488 | $1.26M | $1.79M |
| Operating income | -$1.55M | -$1.21M | -$798,509 | -$609,683 | -$527,902 | -$1.75M | -$1.28M | -$1.20M |
| Pretax income | — | — | — | -$656,885 | -$472,506 | -$1.04M | -$6.11M | -$1.55M |
| Income tax | — | — | — | — | — | — | — | $0 |
| Net income | -$4.58M | -$1.25M | -$810,791 | -$656,885 | -$472,506 | -$1.04M | -$6.11M | -$1.55M |
| EBITDA | — | — | — | — | — | — | — | -$1.20M |
| EPS (basic) | -0.06 | -0.08 | -0.07 | — | -0.04 | -0.09 | -2.15 | — |
| EPS (diluted) | -0.06 | -0.08 | -0.07 | — | -0.04 | -0.09 | -2.15 | — |
| Weighted avg. shares (diluted) | 71.14M | 16.19M | 11.62M | — | 11.62M | 11.33M | 2.84M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $4.26M | $1.63M | $2.60M | $1.83M | $2.32M | $2.92M | $4.59M | $406,408 |
| Current assets | $4.94M | $1.93M | $2.71M | $3.07M | $3.74M | $4.51M | $6.32M | $1.61M |
| Total assets | $5.01M | $1.93M | $2.71M | $3.07M | $3.74M | $4.51M | $6.32M | $1.61M |
| Current liabilities | $1.11M | $492,759 | $735,572 | $299,383 | $347,411 | $592,854 | $935,924 | $3.14M |
| Short-term debt | $299,582 | — | — | — | — | — | — | — |
| Total liabilities | $9.02M | $648,923 | $848,747 | $402,405 | $415,808 | $708,531 | $2.42M | $3.48M |
| Shareholders' equity | -$4.02M | $1.28M | $1.86M | $2.67M | $3.32M | $3.80M | $3.90M | -$1.86M |
| Shares outstanding | 100.07M | 29.12M | 11.62M | 11.62M | 11.62M | 11.62M | 9.59M | 139,168 |
| Cash flow statement | ||||||||
| Operating cash flow | -$881,899 | -$1.39M | $578,584 | -$332,775 | -$445,963 | -$1.38M | -$1.12M | -$1.15M |
| Investing cash flow | — | — | — | $0 | $0 | — | — | $0 |
| Financing cash flow | $4.01M | $420,000 | $195,934 | -$160,241 | -$157,354 | -$154,517 | $5.30M | $0 |
| Depreciation & amortization | — | — | — | — | — | — | — | $0 |
| Stock-based compensation | — | — | — | $0 | $0 | $0 | $20,783 | $28,625 |
Free plan shows the latest 8 periods; Pro shows all 53 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.